Logo do repositório
 
Publicação

Challenges in Antibody Development against Tn and Sialyl-Tn Antigens

2015-08-11Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorLoureiro, Liliana R
dc.contributor.authorCarrascal, Mylène A
dc.contributor.authorBarbas, Ana
dc.contributor.authorRamalho, José S
dc.contributor.authorNovo, Carlos
dc.contributor.authorDelannoy, Philippe
dc.contributor.authorVideira, Paula A
dc.contributor.institutionCentro de Estudos de Doenças Crónicas (CEDOC)
dc.contributor.institutionInstituto de Higiene e Medicina Tropical (IHMT)
dc.contributor.institutionDCV - Departamento de Ciências da Vida
dc.contributor.institutionUCIBIO - Applied Molecular Biosciences Unit
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblMDPI - Multidisciplinary Digital Publishing Institute
dc.date.accessioned2018-05-14T22:03:10Z
dc.date.available2018-05-14T22:03:10Z
dc.date.issued2015-08-11
dc.descriptionPMID: 26270678 PMCID:4598775
dc.description.abstractThe carbohydrate antigens Tn and sialyl-Tn (STn) are expressed in most carcinomas and usually absent in healthy tissues. These antigens have been correlated with cancer progression and poor prognosis, and associated with immunosuppressive microenvironment. Presently they are used in clinical trials as therapeutic vaccination, but with limited success due to their low immunogenicity. Alternatively, anti-Tn and/or STn antibodies may be used to harness the immune system against tumor cells. Whilst the development of antibodies against these antigens had a boost two decades ago for diagnostic use, so far no such antibody entered into clinical trials. Possible limitations are the low specificity and efficiency of existing antibodies and that novel antibodies are still necessary. The vast array of methodologies available today will allow rapid antibody development and novel formats. Following the advent of hybridoma technology, the immortalization of human B cells became a methodology to obtain human monoclonal antibodies with better specificity. Advances in molecular biology including phage display technology for high throughput screening, transgenic mice and more recently molecularly engineered antibodies enhanced the field of antibody production. The development of novel antibodies against Tn and STn taking advantage of innovative technologies and engineering techniques may result in innovative therapeutic antibodies for cancer treatment.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent27
dc.format.extent2322709
dc.identifier.doi10.3390/biom5031783
dc.identifier.issn2218-273X
dc.identifier.otherPURE: 1815250
dc.identifier.otherPURE UUID: 59b8c085-35c2-4b01-a24e-71bd786f8208
dc.identifier.otherPubMed: 26270678
dc.identifier.otherPubMedCentral: PMC4598775
dc.identifier.otherScopus: 85012077616
dc.identifier.otherORCID: /0000-0001-5987-2485/work/43388111
dc.identifier.urihttp://hdl.handle.net/10362/36960
dc.language.isoeng
dc.peerreviewedyes
dc.subjectAnimals
dc.subjectAntibodies
dc.subjectAntigens, Tumor-Associated, Carbohydrate
dc.subjectGenetic Engineering
dc.subjectHumans
dc.subjectImmunotherapy
dc.subjectNeoplasms
dc.subjectJournal Article
dc.subjectResearch Support, Non-U.S. Gov't
dc.subjectReview
dc.subjectSDG 3 - Good Health and Well-being
dc.titleChallenges in Antibody Development against Tn and Sialyl-Tn Antigensen
dc.typejournal article
degois.publication.firstPage1783
degois.publication.issue3
degois.publication.lastPage809
degois.publication.titleBiomolecules
degois.publication.volume5
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Challenges_in_Antibody_Development_against_Tn_and_Sialyl_Tn_Antigens.pdf
Tamanho:
2.22 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

Home collection (FCT)